According to the latest report by IMARC Group, titled “ADME Toxicology Testing Market Report by Technology (Cell Culture, High Throughput Screening, Molecular Imaging, OMICS Technology, and Others), Product Type (Instruments, Software Solutions, Assay Systems, Reagents, and Others), Method (In-Vivo, In-Vitro, In-Silica, and Others), Application (Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, and Others), and Region 2025-2033,” the global ADME toxicology testing market reached a value of USD 10.3 Billion in 2024. Absorption, distribution, metabolism, and excretion (ADME) toxicology testing is performed by researchers in the early phase of the drug development. It assists in discovering and identifying the presence of active metabolites in the plasma and determining the safety, uptake, effectiveness, and metabolic behavior of a drug in living organisms. It also evaluates the safety and toxicity of a drug, thereby saving cost, drug discovery time, and test complications.
Global ADME Toxicology Testing Market Trends:
ADME toxicology testing is widely used to prevent the failure of candidate drugs at late-stage clinical trials and determine the viability of drugs for regulatory approval. This, in confluence with the increasing rate of drug failure and escalating demand for novel drugs, represents one of the significant factors fueling the growth of the market. Moreover, numerous technological advancements to improve the standard of medicines are creating a favorable market outlook. Besides this, the market is also driven by the increasing adoption of innovative software solutions that can calculate ADME automatically. Furthermore, the outbreak of coronavirus disease (COVID-19) has escalated the need for estimating the efficacy of existing drugs as an alternative treatment. This can be accredited to the lack of a vaccine worldwide. Looking forward, the market value is projected to reach USD 30.2 Billion by 2033, expanding at a CAGR of 11.32% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Technology, Product Type, Method, Application, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Bioivt LLC, Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Cyprotex Plc (Evotec AG), Molecular Discovery Ltd., Perkinelmer Inc., Promega Corporation and Thermo Fisher Scientific Inc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal